TXG · 10X Genomics Inc
Snapshot
50 fields · last close| Market Cap | $9.35B |
| P/E | — |
| Float | 115.0M |
| Beta | 1.99 |
| Volatility | 49.8% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 49.4 |
| Price | 73.54 |
| Change | +2.44% |
| Prev Close | 71.79 |
| Open | 74.50 |
| Day Low | 71.25 |
| Day High | 74.55 |
| Avg Vol | 5 |
| Avg $ Vol | $349.0M |
| 52W High | 102.81 |
| 52W Low | 11.16 |
| 52W Pos | 68.1% |
| From High | −28.47% |
| From Low | +558.96% |
| Max DD 1Y | — |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | — |
| SMA 50 | — |
| SMA 200 | — |
| RSI (14) | — |
| Vol 30D | — |
| Vol 90D | — |
| 1Y Range | 11–103 |
| Daily bars | — |
| Perf Week | — |
| Perf Month | — |
| Perf Quarter | — |
| Perf Half Y | — |
| Perf Year | — |
| Perf YTD | — |
| Prev Day | +2.44% |
| Clavix | C- |
| Debt / Eq | 0.04 |
| Curr Ratio | 4.46 |
| Int Cover | -66.1× |
| FCF Margin | 20.2% |
| Rev Growth | +5.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 18 / 19 |
Clavix risk grade
regraded every trading dayTXG grades C-, 49.4 of 100. Steadiest on Sector Resilience (67), most exposed on Price Stability (29, weak). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 18 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| TXG | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.99 | 1.17 |
| Volatilityannualized | 49.8% | 29.3% |
| Max drawdown, past yearworst peak-to-trough fall | — | — |
| Typical daily movemedian absolute daily change | — | — |
| Days beyond ±3%of the last 0 sessions | — | — |
Market sensitivity
| TXG | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.99 | 1.17 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TXG | |
|---|---|
| 1 week | — |
| 1 month | — |
| Year to date | — |
| 1 year | — |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TXG | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 26 Aug |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 24 · 3 |
| Directionarticles whose tone is improving vs worsening | 24 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| TXG | |
|---|---|
| Revenue growthyear over year | +5.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article highlights three stocks outperforming the 'Magnificent Seven' tech leaders this year, citing Moderna's surge on personalized cancer vaccine results and Twist Bioscience's strong demand for its synthetic DNA products.
10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center in early October 2026, applying its Flex Apex, Xenium, and later Atera platforms to biomarker discovery in advanced bladder cancer and detecting remaining disease in acute myeloid leukemia. The article is truncated so further details are unavailable.
10x Genomics is partnering with Fred Hutchinson Cancer Center to advance cancer biomarker research using its single-cell and spatial technologies, with a focus on two specific cancer types.
10x Genomics (TXG) announced a partnership with Fred Hutchinson Cancer Center to research cancer biomarkers, biological signals that help detect or track cancer, using single-cell and spatial technologies, which analyze individual cells and where they sit within tissue. The collaboration will focus on two specific cancer types.
10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single cell and spatial analysis tools across both solid tumors and blood cancers. The work includes biomarker discovery in advanced bladder cancer using the company's Flex Apex and Xenium products, an AML (acute myeloid leukemia, a blood cancer) project for residual disease detection using Flex Apex, and building a framework for future clinical reporting.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| QGEN | Qiagen NV | B+ | $9.36B | 22.97 | 0.60 | Compare |
| BRKR | Bruker Corp | C | $8.56B | — | 1.23 | Compare |
| AVTR | Avantor Inc | B- | $10.52B | — | 0.98 | Compare |
| RGEN | Repligen Corp | B- | $11.14B | 264.15 | 1.12 | Compare |
| TECH | Bio-Techne Corp | B | $11.37B | 62.55 | 1.28 | Compare |
| TEM | Tempus AI Inc | D- | $12.31B | — | 2.15 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.27B | — | 1.38 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.02B | 34.67 | 1.11 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.